Lilly's Tizepatide Cuts Type 2 Diabetes Risk by 94%, New Data Shows
The clinical trial is the longest finalized study of tirzepatide so far. Lilly has only shared top-line datathe main takeaways from the study. The full data will be published in a peer-reviewed journal and presented at amedical conferencein November. Bloomberg / Contributor / Getty Images But there are downsides to the medications, too, including cost and sometimes uncomfortable side effects. A health provider can help you weigh the pros and cons of the drugs....